TC BioPharm develops an allogeneic gamma delta T cell therapy platform that provides scalable, "off the shelf" CAR-T treatments for hematological and solid tumors. This technology reduces side effects and off-tumor toxicity, enabling broader patient access and more efficient manufacturing processes.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current CAR-T therapies for cancer treatment often suffer from significant side effects and off-tumor toxicity, limiting their applicability and creating challenges in manufacturing and patient access. The need for personalized treatments adds complexity and cost to the process.
Solution
TC BioPharm is developing an allogeneic gamma delta T cell therapy platform designed to provide scalable, "off the shelf" CAR-T treatments for both hematological and solid tumors. By utilizing gamma delta T cells, the platform aims to reduce side effects and off-tumor toxicity commonly associated with traditional CAR-T therapies. This approach enables broader patient access through streamlined manufacturing and logistics, while maintaining in-house control over critical elements of drug development, from product development to clinical translation and GMP manufacturing.
Target Audience
The primary target audience includes patients with hematological and solid tumors who are candidates for CAR-T therapy, as well as physicians and hospitals seeking more accessible and less toxic treatment options.
Features
- Allogeneic gamma delta T cell platform for "off the shelf" CAR-T therapies
- Reduced side effects and off-tumor toxicity compared to traditional CAR-T therapies
- Scalable manufacturing processes for efficient production and distribution
- Broad technology platform applicable to both hematological and solid tumors
- Integrated model encompassing product development, clinical development, and manufacturing
- In-house GMP cell and gene manufacturing suites for quality-controlled product creation